{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:23:58Z","timestamp":1773116638149,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jgar.2020.04.017","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T17:11:29Z","timestamp":1588007489000},"page":"689-694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Ceftolozane-tazobactam and ceftazidime-avibactam activity against \u03b2-lactam-resistant Pseudomonas aeruginosa and extended-spectrum \u03b2-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres"],"prefix":"10.1016","volume":"22","author":[{"given":"Elizabeth B.","family":"Hirsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hunter V.","family":"Brigman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola C.","family":"Zucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadyn C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George M.","family":"Eliopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Gilbertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan C.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"Emery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany E.","family":"Bias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2020.04.017_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00355-19","article-title":"The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program","volume":"63","author":"Diekema","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.04.017_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz089","article-title":"The Infectious Diseases Society of America\u2019s 10 x \u201820 Initiative (Ten New Systemic Antibacterial Agents FDA-approved by 2020): is 20 x \u201820 a possibility?","volume":"69","author":"Talbot","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.04.017_bib0015","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2015.05.003","article-title":"Ceftolozane\/tazobactam and ceftazidime\/avibactam: two novel beta-lactam\/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections","volume":"46","author":"Liscio","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2020.04.017_bib0020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciy576","article-title":"Ceftazidime\/avibactam, meropenem\/vaborbactam, or both? Clinical and formulary considerations","volume":"68","author":"Pogue","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.04.017_bib0025","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.04.017_bib0030","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2014.04.004","article-title":"Ceftolozane\/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2020.04.017_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.04.017_bib0040","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1128\/AAC.02398-13","article-title":"Post-beta-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-beta-lactamase-producing strains","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.04.017_bib0045","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1128\/AAC.05024-14","article-title":"Ceftazidime-avibactam activity tested against multidrug-resistant Pseudomonas aeruginosa isolated from United States medical centers (2012-2013)","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.04.017_bib0050","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/AAC.02429-13","article-title":"Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.04.017_bib0055","series-title":"Performance standards for antimicrobial susceptibility testing. 29th ed. M100-S29","author":"Clinical and Laboratory Standards Institute","year":"2019"},{"key":"10.1016\/j.jgar.2020.04.017_bib0060","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ijantimicag.2015.08.012","article-title":"Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates","volume":"46","author":"Hirsch","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2020.04.017_bib0065","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2020.04.017_bib0070","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.04.017_bib0075","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1128\/AAC.03681-14","article-title":"Mutation-driven beta-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.04.017_bib0080","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/AAC.04238-14","article-title":"Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.04.017_bib0085","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates","volume":"60","author":"Buehrle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.04.017_bib0090","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01587-18","article-title":"Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. census divisions: results from the 2017 INFORM program","volume":"62","author":"Sader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.04.017_bib0095","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3343\/alm.2017.37.2.174","article-title":"Susceptibility of ceftolozane-tazobactam and ceftazidime-avibactam against a collection of beta-lactam-resistant gram-negative bacteria","volume":"37","author":"Gonzalez","year":"2017","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.jgar.2020.04.017_bib0100","doi-asserted-by":"crossref","first-page":"e00160","DOI":"10.1128\/AAC.00160-19","article-title":"Comparative activities of ceftazidime-avibactam and ceftolozane-tazobactam against Enterobacteriaceae isolates producing extended-spectrum beta-lactamases from U.S. Hospitals","volume":"63","author":"Castanheira","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520301090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520301090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:55:48Z","timestamp":1761990948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716520301090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":20,"alternative-id":["S2213716520301090"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2020.04.017","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftolozane-tazobactam and ceftazidime-avibactam activity against \u03b2-lactam-resistant Pseudomonas aeruginosa and extended-spectrum \u03b2-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2020.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}